Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05849610
Title Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL)
Acronym GEM-TECTAL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors PETHEMA Foundation
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.